Switch theme
Sign up to access all valuation multiples
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
2005
394
LTM Revenue $226M
LTM EBITDA $14.9M
$1000M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Xeris Biopharma has a last 12-month revenue (LTM) of $226M and a last 12-month EBITDA of $14.9M.
In the most recent fiscal year, Xeris Biopharma achieved revenue of $203M and an EBITDA of -$14.0M.
Xeris Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xeris Biopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $226M | XXX | $203M | XXX | XXX | XXX |
| Gross Profit | $188M | XXX | $166M | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $14.9M | XXX | -$14.0M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | -7% | XXX | XXX | XXX |
| EBIT | -$16.2M | XXX | -$33.6M | XXX | XXX | XXX |
| EBIT Margin | -7% | XXX | -17% | XXX | XXX | XXX |
| Net Profit | -$37.9M | XXX | -$54.8M | XXX | XXX | XXX |
| Net Margin | -17% | XXX | -27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $160M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Xeris Biopharma's stock price is $5.
Xeris Biopharma has current market cap of $790M, and EV of $1000M.
See Xeris Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1000M | $790M | XXX | XXX | XXX | XXX | $-0.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Xeris Biopharma has market cap of $790M and EV of $1000M.
Xeris Biopharma's trades at 4.9x EV/Revenue multiple, and -71.5x EV/EBITDA.
Equity research analysts estimate Xeris Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xeris Biopharma has a P/E ratio of -20.9x.
See valuation multiples for Xeris Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $790M | XXX | $790M | XXX | XXX | XXX |
| EV (current) | $1000M | XXX | $1000M | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | 67.3x | XXX | -71.5x | XXX | XXX | XXX |
| EV/EBIT | -61.6x | XXX | -29.7x | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -20.9x | XXX | -14.4x | XXX | XXX | XXX |
| EV/FCF | -43.0x | XXX | -26.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialXeris Biopharma's last 12 month revenue growth is 28%
Xeris Biopharma's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.5M for the same period.
Xeris Biopharma's rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xeris Biopharma's rule of X is 77% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Xeris Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | -7% | XXX | XXX | XXX |
| EBITDA Growth | 196% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 14% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 77% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 98% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xeris Biopharma acquired XXX companies to date.
Last acquisition by Xeris Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Xeris Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Xeris Biopharma founded? | Xeris Biopharma was founded in 2005. |
| Where is Xeris Biopharma headquartered? | Xeris Biopharma is headquartered in United States of America. |
| How many employees does Xeris Biopharma have? | As of today, Xeris Biopharma has 394 employees. |
| Who is the CEO of Xeris Biopharma? | Xeris Biopharma's CEO is Mr. John P. Shannon. |
| Is Xeris Biopharma publicy listed? | Yes, Xeris Biopharma is a public company listed on NAS. |
| What is the stock symbol of Xeris Biopharma? | Xeris Biopharma trades under XERS ticker. |
| When did Xeris Biopharma go public? | Xeris Biopharma went public in 2018. |
| Who are competitors of Xeris Biopharma? | Similar companies to Xeris Biopharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Xeris Biopharma? | Xeris Biopharma's current market cap is $790M |
| What is the current revenue of Xeris Biopharma? | Xeris Biopharma's last 12 months revenue is $226M. |
| What is the current revenue growth of Xeris Biopharma? | Xeris Biopharma revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of Xeris Biopharma? | Current revenue multiple of Xeris Biopharma is 4.4x. |
| Is Xeris Biopharma profitable? | Yes, Xeris Biopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Xeris Biopharma? | Xeris Biopharma's last 12 months EBITDA is $14.9M. |
| What is Xeris Biopharma's EBITDA margin? | Xeris Biopharma's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Xeris Biopharma? | Current EBITDA multiple of Xeris Biopharma is 67.3x. |
| What is the current FCF of Xeris Biopharma? | Xeris Biopharma's last 12 months FCF is -$23.2M. |
| What is Xeris Biopharma's FCF margin? | Xeris Biopharma's last 12 months FCF margin is -10%. |
| What is the current EV/FCF multiple of Xeris Biopharma? | Current FCF multiple of Xeris Biopharma is -43.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
